Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene Glycol SCHEMBL5092840 | 0.94 | PTGS1 (0.46) | PTGS1PTGS2MEN1KMT2AGAA | |
| SCHEMBL7463384 | 0.94 | PTGS1 (0.58) | PTGS1PTGS2MEN1KMT2AGAA | |
| SCHEMBL27248010 | 0.92 | PTGS1 (0.61) | PTGS1PTGS2MEN1KMT2AGAA | |
| SCHEMBL5698008 | 0.92 | PTGS1 (0.61) | PTGS1PTGS2MEN1KMT2AGAA | |
| SCHEMBL9410394 | 0.92 | PTGS1 (0.61) | PTGS1PTGS2MEN1KMT2AGAA | |
| SCHEMBL5697933 | 0.92 | PTGS1 (0.61) | PTGS1PTGS2MEN1KMT2AGAA | |
| SCHEMBL1618771 | 0.92 | PTGS1 (0.61) | PTGS1PTGS2MEN1KMT2AGAA | |
| SCHEMBL7259687 | 0.92 | PTGS1 (0.61) | PTGS1PTGS2MEN1KMT2AGAA | |
| SCHEMBL5698003 | 0.92 | PTGS1 (0.61) | PTGS1PTGS2MEN1KMT2AGAA | |
| SCHEMBL11009569 | 0.92 | PTGS1 (0.61) | PTGS1PTGS2MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3689898-B1 | LONG-ACTING CONJUGATE OF GLUCAGON-LIKE PEPTIDE-2 (GLP-2) DERIVATIVE | HANMI PHARMACEUTICAL CO LTD (KR) | 2026-04-29 | — | — | EP | claimed |
| EP-2963055-B1 | SITE-SPECIFIC INSULIN CONJUGATE | HANMI PHARM IND CO LTD (KR) | 2019-05-15 | — | — | EP | claimed |
| EP-2799539-B1 | HUMAN ARGINASE AND FIXED-POINT PEGYLATED HUMAN ARGINASE AND USE THEREOF | BIO-CANCER TREAT INT LTD (SHANGHAI) (CN) | 2017-09-13 | — | — | EP | claimed |
| EP-1646661-B1 | LIVING RADICAL POLYMERIZATION INITIATOR COMPRISING A FUNCTIONAL GROUP CAPABLE OF REACTING WITH POLYPEPTIDES OR THE LIKE, COMB POLYMER OBTAINED THEREWITH, POLYPEPTIDE CONJUGATES AND DRUNG OBTAINED THEREFROM | WARWICK EFFECT POLYMERS LTD (GB) | 2009-04-01 | — | — | EP | claimed |
| EP-1476489-B8 | HYDROLYTICALLY DEGRADABLE ALKYLENE OXIDE BASED POLYMERS | NEKTAR THERAPEUTICS AL CORP (US) | 2008-10-08 | — | — | EP | claimed |
| EP-1345982-B1 | SYNTHESIS OF HIGH MOLECULAR WEIGHT NON-PEPTIDIC POLYMER DERIVATIVES | NEKTAR THERAPEUTICS AL CORP (US) | 2007-04-25 | — | — | EP | claimed |
| US-20060239961-A1 | Hydrolytically degradable alkylene oxide based polymers | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2006-10-26 | — | — | US | claimed |
| EP-1476489-A1 | HYDROLYTICALLY DEGRADABLE ALKYLENE OXIDE BASED POLYMERS | Nektar Therapeutics Al, Corporation (US) | 2004-11-17 | — | — | EP | claimed |
| WO-2003070805-A1 | HYDROLYTICALLY DEGRADABLE ALKYLENE OXIDE BASED POLYMERS | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2003-08-28 | — | — | WO | claimed |
| US-20030023023-A1 | Hydrolytically degradable polymers and hydrogels made therefrom | SHEARWATER CORPORATION | 2003-01-30 | — | — | US | claimed |
| US-6348558-B1 | OLIGOMERS COMPRISING ALKYLENE OXIDE MONOMERS AND CARBONATE LINKAGES; POLYCARBONATEETHER COPOLYMERS; DRUG DELIVERY; CONJUGATED TO PEPTIDES OR PROTEINS FOR REDUCED IMMUNOGENICITY; STABILITY | SHEARWATER CORPORATION | 2002-02-19 | — | — | US | claimed |
| EP-0366041-B2 | Imido-percarboxylic acids | AUSIMONT SPA (IT) | 2001-09-12 | — | — | EP | claimed |
| EP-0366041-B1 | Imido-percarboxylic acids | AUSIMONT SPA (IT) | 1998-08-05 | — | — | EP | claimed |
| EP-0366041-A2 | Imido-percarboxylic acids | AUSIMONT S.r.l. (IT) | 1990-05-02 | — | — | EP | claimed |
| US-20250388934-A1 | PROTEIN HAVING NUCLEASE ACTIVITY, FUSION PROTEINS AND USES THEREOF | HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH (DE) | 2025-12-25 | — | — | US | disclosed |
| WO-2025233381-A1 | ENZYMES THAT ELIMINATE PYRIMIDINE AND/OR PURINE NUCLEOSIDES FOR TREATING CANCER | Technische Universität München, in Vertretung des Freistaates Bayern (DE) | 2025-11-13 | — | — | WO | disclosed |
| EP-4554677-A1 | BINDING MOLECULES FOR THE TREATMENT OF CANCER | Boehringer Ingelheim International GmbH (DE) | 2025-05-21 | — | — | EP | disclosed |
| EP-0366041-B1 | Imido-percarboxylic acids | AUSIMONT SPA (IT) | 1998-08-05 | — | — | EP | disclosed |
| US-5536434-A | BLEACHES | AUSIMONT S.P.A. (IT) | 1996-07-16 | — | — | US | disclosed |
| EP-0366041-A2 | Imido-percarboxylic acids | AUSIMONT S.r.l. (IT) | 1990-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060239961-A1 | Hydrolytically degradable alkylene oxide based polymers | HAO2, IDE, APEH | PTGS1 411/4885PTGS2 264/4885MEN1 3777/4885 |
| US-20250388934-A1 | PROTEIN HAVING NUCLEASE ACTIVITY, FUSION PROTEINS AND USES THEREOF | DNASE1, DNASE1L3, NUDT21 | PTGS1 3647/4885PTGS2 3835/4885MEN1 2074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.